CO2022000041A2 - Vesículas extracelulares microbianas secretadas - Google Patents

Vesículas extracelulares microbianas secretadas

Info

Publication number
CO2022000041A2
CO2022000041A2 CONC2022/0000041A CO2022000041A CO2022000041A2 CO 2022000041 A2 CO2022000041 A2 CO 2022000041A2 CO 2022000041 A CO2022000041 A CO 2022000041A CO 2022000041 A2 CO2022000041 A2 CO 2022000041A2
Authority
CO
Colombia
Prior art keywords
extracellular vesicles
microbial extracellular
secreted microbial
secreted
smevs
Prior art date
Application number
CONC2022/0000041A
Other languages
English (en)
Inventor
Brian Goodman
Christopher Jh Davitt
Erin B Troy
Alicia Ballok
Mark Bodmer
Baundauna Bose
Sofia M R Carlton
Taylor A Cormack
Loise Francisco-Anderson
Andrea Itano
Nihal Okan
Holly Ponichtera
Fabian B Romano-Chernac
Maria Sizova
Original Assignee
Evelo Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evelo Biosciences Inc filed Critical Evelo Biosciences Inc
Publication of CO2022000041A2 publication Critical patent/CO2022000041A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

En el presente documento se proporcionan métodos y composiciones farmacéuticas relacionados con vesículas extracelulares microbianas secretadas (smEV) que pueden ser útiles como agentes terapéuticos.
CONC2022/0000041A 2019-06-11 2022-01-05 Vesículas extracelulares microbianas secretadas CO2022000041A2 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962860049P 2019-06-11 2019-06-11
US201962860029P 2019-06-11 2019-06-11
US202062979545P 2020-02-21 2020-02-21
US202062991767P 2020-03-19 2020-03-19
PCT/US2020/037201 WO2020252144A1 (en) 2019-06-11 2020-06-11 Secreted microbial extracellular vesicles

Publications (1)

Publication Number Publication Date
CO2022000041A2 true CO2022000041A2 (es) 2022-01-17

Family

ID=71950732

Family Applications (2)

Application Number Title Priority Date Filing Date
CONC2022/0000040A CO2022000040A2 (es) 2019-06-11 2022-01-05 Vesículas extracelulares microbianas procesadas
CONC2022/0000041A CO2022000041A2 (es) 2019-06-11 2022-01-05 Vesículas extracelulares microbianas secretadas

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CONC2022/0000040A CO2022000040A2 (es) 2019-06-11 2022-01-05 Vesículas extracelulares microbianas procesadas

Country Status (12)

Country Link
US (2) US20220249579A1 (es)
EP (2) EP3982987A1 (es)
JP (2) JP2022537684A (es)
KR (2) KR20220020894A (es)
CN (2) CN114096262A (es)
AU (2) AU2020291434A1 (es)
BR (2) BR112021024830A2 (es)
CA (2) CA3143025A1 (es)
CO (2) CO2022000040A2 (es)
MX (2) MX2021015427A (es)
TW (2) TW202128198A (es)
WO (2) WO2020252149A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200118100A (ko) * 2018-02-06 2020-10-14 에벨로 바이오사이언시즈, 인크. 베일로넬라 박테리아를 이용한 암 및 면역 장애를 치료하기 위한 조성물 및 방법
KR102286042B1 (ko) * 2019-01-09 2021-08-03 주식회사 엠디헬스케어 데이노코커스 속 세균 유래 나노소포 및 이의 용도
WO2021252861A1 (en) * 2020-06-11 2021-12-16 Evelo Biosciences, Inc. Compositions and methods for treating diseases and disorders using megasphaera sp
EP4164666A2 (en) * 2020-06-11 2023-04-19 Evelo Biosciences, Inc. Compositions and methods for treating diseases and disorders using harryflintia acetispora
KR20230053609A (ko) * 2020-07-21 2023-04-21 에벨로 바이오사이언시즈, 인크. 신경염증성 질환에 대한 경구 요법으로서의 베일로넬라 파르불라 균주
WO2022061119A1 (en) * 2020-09-21 2022-03-24 Evelo Biosciences, Inc. Compositions and methods for modulating immune responses with prevotella histicola
KR20230137968A (ko) * 2021-01-26 2023-10-05 에벨로 바이오사이언시즈, 인크. 프레보텔라 세포외 소포체 제제
WO2022178209A1 (en) * 2021-02-19 2022-08-25 Evelo Biosciences, Inc. Compositions and methods for treating metabolic diseases and disorders using christensenellaceae bacteria
WO2022221183A1 (en) * 2021-04-12 2022-10-20 Evelo Biosciences, Inc. Fournierella extracellular vesicle preparations
WO2022251166A2 (en) * 2021-05-25 2022-12-01 Evelo Biosciences, Inc. Bacterial compositions comprising soy hemoglobin
WO2023114300A1 (en) * 2021-12-14 2023-06-22 Evelo Biosciences, Inc. Fournierella massiliensis bacteria extracellular vesicle preparations
WO2023114293A1 (en) * 2021-12-14 2023-06-22 Evelo Biosciences, Inc. Extracellular vesicle assays
WO2023146843A1 (en) * 2022-01-25 2023-08-03 Evelo Biosciences, Inc. Extracellular vesicle compositions and methods of use
WO2023239728A1 (en) * 2022-06-07 2023-12-14 Evelo Biosciences, Inc. Compositions and methods of treating inflammation using prevotella histicola extracellular vesicles

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101858840B1 (ko) * 2016-01-15 2018-05-16 단국대학교 천안캠퍼스 산학협력단 집먼지진드기 유래 알레르겐에 의한 과민반응 면역조절제
AU2018298087A1 (en) * 2017-07-05 2020-01-23 Evelo Biosciences, Inc. Compositions and methods of treating cancer using bifidobacterium animalis ssp. lactis
TW201920648A (zh) * 2017-08-29 2019-06-01 美商艾弗洛生物科技股份有限公司 使用布勞特氏(blautia)菌株治療癌症
CN111148531A (zh) * 2017-09-08 2020-05-12 伊夫罗生物科学公司 细菌胞外囊泡
KR20200053532A (ko) * 2017-09-08 2020-05-18 에벨로 바이오사이언시즈, 인크. 프레보텔라로부터의 세포외 소포
EP3710023A1 (en) * 2017-11-14 2020-09-23 Evelo Biosciences, Inc. Compositions and methods for treating disease using a blautia strain
KR20200090189A (ko) * 2017-11-15 2020-07-28 에벨로 바이오사이언시즈, 인크. 면역조절 락토코쿠스 박테리아 균주를 사용하여 면역 장애를 치료하기 위한 조성물 및 방법
CN109580960A (zh) * 2019-01-14 2019-04-05 周明 细胞外囊泡的分离方法、以及检测细胞外囊泡表面标志物的方法和试剂盒

Also Published As

Publication number Publication date
CA3143036A1 (en) 2020-12-17
WO2020252144A1 (en) 2020-12-17
CO2022000040A2 (es) 2022-01-17
EP3982986A1 (en) 2022-04-20
KR20220020893A (ko) 2022-02-21
BR112021024830A2 (pt) 2022-04-12
CA3143025A1 (en) 2020-12-17
KR20220020894A (ko) 2022-02-21
US20220296654A1 (en) 2022-09-22
MX2021015429A (es) 2022-01-24
BR112021024754A2 (pt) 2022-04-19
AU2020291003A1 (en) 2022-01-06
AU2020291434A1 (en) 2022-01-06
WO2020252149A1 (en) 2020-12-17
JP2022537684A (ja) 2022-08-29
JP2022538765A (ja) 2022-09-06
US20220249579A1 (en) 2022-08-11
EP3982987A1 (en) 2022-04-20
TW202114718A (zh) 2021-04-16
CN114096262A (zh) 2022-02-25
CN114650831A (zh) 2022-06-21
MX2021015427A (es) 2022-01-24
TW202128198A (zh) 2021-08-01

Similar Documents

Publication Publication Date Title
CO2022000041A2 (es) Vesículas extracelulares microbianas secretadas
CO2020004233A2 (es) Vesículas extracelulares bacterianas
CO2021012176A2 (es) Preparaciones de membrana bacteriana
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
CO2020005887A2 (es) Compuestos policíclicos como inhibidores alostéricos de shp2
PE20181139A1 (es) Composiciones y metodos para inhibir la expresion genica de lpa
AR113881A1 (es) Composiciones y métodos para el tratamiento de desórdenes inmunes usando la cepa blautia
CL2019003398A1 (es) Inhibidores pirazólicos de magl.
DOP2013000104A (es) Antagonistas de mdm2 de espiro-oxindol
CO6680708A2 (es) Compuesto modulares de estrógenos y composiciones que comprenden los mismos
EA201692334A1 (ru) Кортикостероидные композиции для местного применения
CL2019003397A1 (es) Inhibidores pirazólicos de magl.
CO2023000114A2 (es) Composiciones y métodos para el tratamiento de enfermedades y trastornos usando vesículas extracelulares microbianas de oscillospiraceae
CL2020003447A1 (es) Composiciones y métodos para el tratamiento de enfermedades o condiciones relacionadas con inflamasomas
ECSP20082988A (es) Agonistas de tlr7
CO6761294A2 (es) Derivados de pirazol que modulan la estearoil-coa-desaturasa
CL2020000019A1 (es) Agentes de iarn para la inhibición de la expresión de alfa-enac y métodos de uso.
CO2018008626A2 (es) Formulaciones de oritavancina
AR119272A1 (es) Vesículas extracelulares microbianas secretadas
NI201200196A (es) Agentes terapéuticos 976
AR122608A1 (es) Composiciones y métodos para el tratamiento de enfermedades y trastornos usando harryflintia acetispora
AR122609A1 (es) Composiciones y métodos para el tratamiento de enfermedades y trastornos usando fournierella massiliensis
AR114282A1 (es) Inhibidores de secreción de proteínas basados en triazaciclododecansulfonamida (“tcd”)
CO2020012484A2 (es) Inhibidores de secreción de proteínas basados en triazaciclododecansulfonamida ("tcd")
AR122607A1 (es) Composiciones y métodos para el tratamiento de enfermedades y trastornos usando megasphaera sp.